Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.50 |
| ▸ | CRHR1 | P34998 | 11/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599426 | 0.92 | CRHR1 (0.57) | NR4A2CRHR1TP53CD38 | |
| SCHEMBL5707856 | 0.89 | CRHR1 (0.46) | NR4A2CRHR1TP53CD38 | |
| SCHEMBL5599396 | 0.85 | CRHR1 (0.53) | NR4A2CRHR1TP53CD38 | |
| SCHEMBL5599486 | 0.79 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL7077097 | 0.75 | CRHR1 (0.59) | NR4A2CRHR1TP53 | |
| SCHEMBL7221799 | 0.72 | CRHR1 (0.48) | CRHR1CD38 | |
| SCHEMBL7220635 | 0.72 | CRHR1 (0.41) | CRHR1CD38 | |
| SCHEMBL6094492 | 0.72 | CRHR1 (0.56) | NR4A2CRHR1TP53CD38 | |
| SCHEMBL7615502 | 0.70 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL5600092 | 0.70 | CRHR1 (0.57) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | claimed |
| US-6432989-B1 | TREATING SLEEP DISORDERS | PFIZER INC | 2002-08-13 | — | — | US | claimed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1703918-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | disclosed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0925298-A1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998008846-A1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | CRH, MC2R, CRHR2 | NR4A2 1262/4885CRHR1 5/4885TP53 1761/4885 |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | NR4A2 125/4885CRHR1 2/4885TP53 4880/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | NR4A2 540/4885CRHR1 2/4885TP53 4765/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | NR4A2 125/4885CRHR1 2/4885TP53 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.